InterVenn Biosciences

10:45 AM - 11:00 AM (EDT), Wednesday, October 23, 2019 ・ 2nd Floor
InterVenn Biosciences utilizes a proprietary glycoproteomic biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine. Our applications include diagnostics/prognostics for ovarian, pancreatic, liver, breast and kidney cancer together with applications (using our “Vista” suite of solutions) in treatment prediction/monitoring, immune profiling, patient stratification, and disease progression.

Aberrant glycosylation of proteins has been implicated in key steps of disease biology, including the hallmarks of cancer as well as inflammation cascades associated with autoimmunity and aging. Glycoproteins have been analytically and computationally challenging to study at scale. We have built a platform that overcomes these challenges while turning years of computational burden into minutes.

We are currently conducting a 3-country clinical trial for our OvCa diagnostic and offer our Vista programs to many biopharma and academic institutions globally.
Company Type:
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Lead Product in Development:
Ovarian Cancer
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
InterVenn Biosciences